Low-dose oral etoposide (E) + DDI in patients (pts) with AIDS-related neoplasias (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Low-dose oral etoposide (E) + DDI in patients (pts) with AIDS-related neoplasias (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A12 1994. Unique Identifier : AIDSLINE ICDB/94600009
Schmilovich A; Perez H; Gil Deza E; Cahn P; Casiro A; Grinberg N; Fundacion Huesped, Arcos 2626, 428, Buenos Aires, Argentina

Abstract: E is a topoisomerase II inhibitor whose activity is schedule-dependent. Previous studies suggest that prolonged exposition to low concentrations are more cytotoxic than short exposition to high concentrations. Recent studies had shown also that E is active by oral route. AIDS pts have an increased incidence of E sensible neoplasia (Kaposi Sarcoma (KS)) and Non-Hodgkin's lymphoma (NHL), but it's not feasible to combine with AZT due to severe myelotoxicity and/or infections. In this Phase II trial E was given at the dose of 30 mg/m2 bid for 14 days every weeks. Up to now 24 pts (15 KS, 8 NHL, 1 small-cell lung cancer (SCLC)) were included. Median age was 31 years (r23-45) KS: Stage IIIB: 3; IIIA: 6; IVB: 6 (according NY/U criteria). NHL: Stage IVA: 5; IVB:3 (according to Ann Arbor criteria) and SCLC Stage IV (according to TNM system). All pts received DDI plus cotrimoxazole during all courses, 6/15 KS relapsed after interferon therapy and 2/8 NHL relapsed after radiotherapy were included. Median performance status (ECOS) was 2 (r2-3). A median of 4 courses per pt (r2-5) was given. Overall response (CR+PR) was 37% (9/24). One pt achieved CR (SCLC). Median time to progression was 6 mo (r4 +/- 10). 5 pts developed opportunistic infections (tuberculosis: 3, toxoplasmosis; 1, pneumocystis: 1). Major toxicities were leukopenia (WHO Grade III-IV 62/80 courses) alopecia (WHO Grade III: 10 pts). No pt except 4 were admitted to the hospital except for the treatment of opportunistic infection. Hematological support (GM-CSF) was required in 12 pts. Preliminary results suggest that E by oral route combined with DDI is an active regimen in AIDS related neoplasias suitable for outpatient administration, main toxicity is hematological but manageable with GM-CSF.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/PATHOLOGY Administration, Oral Adult Carcinoma, Small Cell/DRUG THERAPY/PATHOLOGY Didanosine/*ADMINISTRATION & DOSAGE Dose-Response Relationship, Drug Drug Therapy, Combination Etoposide/*ADMINISTRATION & DOSAGE Human Lung Neoplasms/DRUG THERAPY/PATHOLOGY Lymphoma, AIDS-Related/*DRUG THERAPY/PATHOLOGY Neoplasm Staging Sarcoma, Kaposi's/*DRUG THERAPY/PATHOLOGY Skin Neoplasms/*DRUG THERAPY/PATHOLOGY ABSTRACT CLINICAL TRIAL CLINICAL TRIAL, PHASE IIKWDacquiredimmunodeficiencysyndrome/KWDdrugtherapy/pathologyadministration,oraladultcarcinoma,smallcell/drugtherapy/pathologydidanosine/KWDadministration&dosagedose-responserelationship,drugdrugtherapy,combinationetoposide/KWDadministration&dosagehumanlungneoplasms/drugtherapy/pathologylymphoma,aids-related/KWDdrugtherapy/pathologyneoplasmstagingsarcoma,kaposi's/KWDdrugtherapy/pathologyskinneoplasms/KWDdrugtherapy/pathologyabstractclinicaltrialclinicaltrial,phaseii
940830
M9480789

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .